SepsisNCT04740333
Prognostic Impact of Admission Glucose Level in Septic Patients Admitted to the Intensive Care Unit
An observational study of Sepsis, run by Meir Medical Center at 1 site in Israel.
Trial summary
Background: Sepsis is one of the most common reasons for admission to intensive care units (ICU) worldwide. About 30% of all patients admitted to intensive care suffer from sepsis (1). Sepsis causes an extreme physiological stress response, with significant changes in metabolism and disruption in glucose regulation. Read more about this study
- Who is it for?
- Ages 18 to 99 years
- Conditions the study is for
- Sepsis
- How many people
- 224 participants
- Where
- 1 siteIsrael
- Study dates
- 1 Dec 2023to 1 Feb 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Non-diabetic patients aged 18-99 who were admitted to the ICU between 1.1.2014 and 30.1.2020 due to sepsis or septic shock.
Inclusion Criteria:1. Patients admitted to the ICU between 1.1.2014-30.1.2020. 2. Diagnosis of sepsis or septic shock upon admission. 3. Age over 18 years. 4. No previous diagnosis of diabetes mellitus.
-
Exclusion Criteria:1. Patients with prior diagnosis of diabetes mellitus. 2. Admission hypoglycemia (blood glucose levels below 70 mg / dL). 3. Patients who were given insulin or intravenous glucose before the first ICU blood glucose measured level.
-
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Prognostic Impact of Admission Glucose Level in Septic Patients Admitted to the Intensive Care Unit- a Retrospective Study
Background:
Sepsis is one of the most common reasons for admission to intensive care units (ICU) worldwide. About 30% of all patients admitted to intensive care suffer from sepsis (1). Sepsis causes an extreme physiological stress response, with significant changes in metabolism and disruption in glucose regulation. Disorder of glucose regulation can lead to hyperglycemia, hypoglycemia and glucose variability (2). All of these conditions are associated with increased mortality (3). In critically-ill patients, the glucose threshold from which damage may be caused remains controversial.
Read more
Hyperglycemia often occurs in critically-ill patients suffering from sepsis, even in those who were not diabetic before, for several reasons. Sepsis causes massive activation of anti-inflammatory mediators which enhances the activity of counter-regulatory hormones, including cortisol, glucagon and catecholamines. Those hormones increase both hepatic gluconeogenesis and peripheral resistance to insulin (4). Some of the detrimental effects of hyperglycemia in septic patients are mediated via hyperglycemia-induced blood hypercoagulable state, decrease of vascular endothelial responsiveness and disrupted process of phagocytosis and chemotaxis of white blood cells, especially neutrophils (5).
It is widely accepted that disordered blood glucose regulation increases mortality and morbidity, as well as hospital admission times and associated financial expenses (2,6). Blood glucose level at ICU admission was found to be a poor prognostic factor at various studies on different ICU patient populations (7-9). For example, in ICU patients admitted due to acute myocardial infarction, cardiogenic shock and need for urgent cardiac catheterization, high blood glucose levels at admission, even in non-diabetic patients, were associated with both increased in- hospital and long-term mortality (7). Among patients admitted due to acute heart failure, high admission glucose levels (above 200 mg / dL), in both diabetic and non-diabetic patients, were associated with higher mortality from cardio-vascular etiologies within one year of admission (8). Among non-diabetic patients admitted to the hospital due to acute myocardial infarction, admission glucose levels above 180 mg / dL were associated with a significant increase in all-causes in-hospital mortality (9). However, there is currently insufficient information regarding the prognostic impact of high admission glucose levels of non-diabetic septic patients admitted to the ICU (10).
Read the detailed description
Background:
Sepsis is one of the most common reasons for admission to intensive care units (ICU) worldwide. About 30% of all patients admitted to intensive care suffer from sepsis (1). Sepsis causes an extreme physiological stress response, with significant changes in metabolism and disruption in glucose regulation. Disorder of glucose regulation can lead to hyperglycemia, hypoglycemia and glucose variability (2). All of these conditions are associated with increased mortality (3). In critically-ill patients, the glucose threshold from which damage may be caused remains controversial.
Hyperglycemia often occurs in critically-ill patients suffering from sepsis, even in those who were not diabetic before, for several reasons. Sepsis causes massive activation of anti-inflammatory mediators which enhances the activity of counter-regulatory hormones, including cortisol, glucagon and catecholamines. Those hormones increase both hepatic gluconeogenesis and peripheral resistance to insulin (4). Some of the detrimental effects of hyperglycemia in septic patients are mediated via hyperglycemia-induced blood hypercoagulable state, decrease of vascular endothelial responsiveness and disrupted process of phagocytosis and chemotaxis of white blood cells, especially neutrophils (5).
It is widely accepted that disordered blood glucose regulation increases mortality and morbidity, as well as hospital admission times and associated financial expenses (2,6). Blood glucose level at ICU admission was found to be a poor prognostic factor at various studies on different ICU patient populations (7-9). For example, in ICU patients admitted due to acute myocardial infarction, cardiogenic shock and need for urgent cardiac catheterization, high blood glucose levels at admission, even in non-diabetic patients, were associated with both increased in- hospital and long-term mortality (7). Among patients admitted due to acute heart failure, high admission glucose levels (above 200 mg / dL), in both diabetic and non-diabetic patients, were associated with higher mortality from cardio-vascular etiologies within one year of admission (8). Among non-diabetic patients admitted to the hospital due to acute myocardial infarction, admission glucose levels above 180 mg / dL were associated with a significant increase in all-causes in-hospital mortality (9). However, there is currently insufficient information regarding the prognostic impact of high admission glucose levels of non-diabetic septic patients admitted to the ICU (10).
Outcomes:
Main outcome: To study the correlation between high blood glucose levels (above 180 mg / dL) upon ICU admission of non-diabetic patients with sepsis, and 28-day mortality, compared to ICU admitted septic patients with normal blood glucose levels upon admission (less than 180 mg / dL and above 70 mg / dL).
Secondary outcomes: To study the correlation between high blood glucose levels (above 180 mg / dL) upon ICU admission of non-diabetic patients with sepsis, and morbidity parameters, such as ventilation days, vasopressor and inotropic support, need for dialysis, need for tracheostomy, APACHE-2 score and admission lactate level compared to ICU admitted septic patients with normal blood glucose levels upon admission (less than 180 mg / dL and above 70 mg / dL).
Materials and methods:
Study design: Cohort retrospective study. Study population: Non-diabetic patients aged 18-99 who were admitted to the ICU between 1.1.2014 and 30.1.2020 due to sepsis or septic shock.
Study groups: Group A - Patients with admission blood glucose level lower than 180 mg / dL (but higher than 70 mg / dL).
Group B- Patients with admission blood glucose level higher than 180 mg / dL. Inclusion criteria: 1. Patients admitted to the ICU between 1.1.2014-30.1.2020. 2. Diagnosis of sepsis or septic shock upon admission. 3. Age over 18 years. 4. No previous diagnosis of diabetes mellitus. Exclusion criteria: 1. Patients with prior diagnosis of diabetes mellitus. 2. Admission hypoglycemia (blood glucose levels below 70 mg / dL). 3. Patients who were given insulin or intravenous glucose before the first ICU blood glucose measured level.
Data collection: Observational data collection format from hospital files and computerized systems (Chameleon system and iMDsoft software).
Data to be collected: age, gender, ICU and hospital admission times, source of infection, ventilation days, pressor or inotropic support, 28-day mortality, past medical history including regular medications, APACHE-2 score, admission lactate level, need for dialysis and need for tracheostomy.
Study group size: 1000 patients. Statistical analysis: All the parameters will be statistically examined by a qualified statistician depending on the type of data. We will use the Chi square test to analyze the individual data and the Mann-Whitney test to analyze the continuous data.
- Conditions
- Sepsis
- Being tested
- No intervention- observational study
- Medical subject headings
- Sepsis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No intervention- observational studyOther
No intervention- observational study
| Study group | Role | What they receive |
|---|---|---|
| Group A- Normal ICU admission blood glucose level | Patients with admission blood glucose level lower than 180 mg / dL (but higher than 70 mg / dL). Receives: Other: No intervention- observational study | |
| Group B- High ICU admission blood glucose level | Patients with admission blood glucose level higher than 180 mg / dL. Receives: Other: No intervention- observational study |
What is being measured
The primary outcome is the main question the study is designed to answer.
28-day mortality
To study the correlation between high blood glucose levels (above 180 mg / dL) upon ICU admission of non-diabetic patients with sepsis, and 28-day mortality, compared to ICU admitted septic patients with normal blood glucose levels upon admission (less than 180 mg / dL and above 70 mg / dL).
Measured: 28-day from ICU admission
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Feb 2021
- Study start1 Dec 2023
- Primary completion1 Feb 2024
- Study completion1 Feb 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SepsisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 224 participants (actual)
Sponsor and investigators
- Lead sponsor
- Meir Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, sara dichtwald, Meir Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04740333
- Sponsor's protocol ID
- 0384-20-MMC
- Status last verified
- Mar 2024
- First submitted
- 2 Feb 2021
- Last updated
- 15 Mar 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Mar 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prognostic Impact of Admission Glucose Level in Septic Patients Admitted to the Intensive Care Unit- a Retrospective Study
- ClinicalTrials.gov ID
- NCT04740333
- Acronym / sponsor ID
- 0384-20-MMC
- Conditions
- Sepsis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 224 participants (actual)
- Lead sponsor
- Meir Medical CenterUniversity, hospital or other
- Study start
- 1 Dec 2023 (actual)
- Primary completion
- 1 Feb 2024 (actual)
- Study completion
- 1 Feb 2024 (actual)
- First posted
- 5 Feb 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background:
Sepsis is one of the most common reasons for admission to intensive care units (ICU) worldwide. About 30% of all patients admitted to intensive care suffer from sepsis (1). Sepsis causes an extreme physiological stress response, with significant changes in metabolism and disruption in glucose regulation. Disorder of glucose regulation can lead to hyperglycemia, hypoglycemia and glucose variability (2). All of these conditions are associated with increased mortality (3). In critically-ill patients, the glucose threshold from which damage may be caused remains controversial.
Hyperglycemia often occurs in critically-ill patients suffering from sepsis, even in those who were not diabetic before, for several reasons. Sepsis causes massive activation of anti-inflammatory mediators which enhances the activity of counter-regulatory hormones, including cortisol, glucagon and catecholamines. Those hormones increase both hepatic gluconeogenesis and peripheral resistance to insulin (4). Some of the detrimental effects of hyperglycemia in septic patients are mediated via hyperglycemia-induced blood hypercoagulable state, decrease of vascular endothelial responsiveness and disrupted process of phagocytosis and chemotaxis of white blood cells, especially neutrophils (5).
It is widely accepted that disordered blood glucose regulation increases mortality and morbidity, as well as hospital admission times and associated financial expenses (2,6). Blood glucose level at ICU admission was found to be a poor prognostic factor at various studies on different ICU patient populations (7-9). For example, in ICU patients admitted due to acute myocardial infarction, cardiogenic shock and need for urgent cardiac catheterization, high blood glucose levels at admission, even in non-diabetic patients, were associated with both increased in- hospital and long-term mortality (7). Among patients admitted due to acute heart failure, high admission glucose levels (above 200 mg / dL), in both diabetic and non-diabetic patients, were associated with higher mortality from cardio-vascular etiologies within one year of admission (8). Among non-diabetic patients admitted to the hospital due to acute myocardial infarction, admission glucose levels above 180 mg / dL were associated with a significant increase in all-causes in-hospital mortality (9). However, there is currently insufficient information regarding the prognostic impact of high admission glucose levels of non-diabetic septic patients admitted to the ICU (10).
Detailed description
Background:
Sepsis is one of the most common reasons for admission to intensive care units (ICU) worldwide. About 30% of all patients admitted to intensive care suffer from sepsis (1). Sepsis causes an extreme physiological stress response, with significant changes in metabolism and disruption in glucose regulation. Disorder of glucose regulation can lead to hyperglycemia, hypoglycemia and glucose variability (2). All of these conditions are associated with increased mortality (3). In critically-ill patients, the glucose threshold from which damage may be caused remains controversial.
Hyperglycemia often occurs in critically-ill patients suffering from sepsis, even in those who were not diabetic before, for several reasons. Sepsis causes massive activation of anti-inflammatory mediators which enhances the activity of counter-regulatory hormones, including cortisol, glucagon and catecholamines. Those hormones increase both hepatic gluconeogenesis and peripheral resistance to insulin (4). Some of the detrimental effects of hyperglycemia in septic patients are mediated via hyperglycemia-induced blood hypercoagulable state, decrease of vascular endothelial responsiveness and disrupted process of phagocytosis and chemotaxis of white blood cells, especially neutrophils (5).
It is widely accepted that disordered blood glucose regulation increases mortality and morbidity, as well as hospital admission times and associated financial expenses (2,6). Blood glucose level at ICU admission was found to be a poor prognostic factor at various studies on different ICU patient populations (7-9). For example, in ICU patients admitted due to acute myocardial infarction, cardiogenic shock and need for urgent cardiac catheterization, high blood glucose levels at admission, even in non-diabetic patients, were associated with both increased in- hospital and long-term mortality (7). Among patients admitted due to acute heart failure, high admission glucose levels (above 200 mg / dL), in both diabetic and non-diabetic patients, were associated with higher mortality from cardio-vascular etiologies within one year of admission (8). Among non-diabetic patients admitted to the hospital due to acute myocardial infarction, admission glucose levels above 180 mg / dL were associated with a significant increase in all-causes in-hospital mortality (9). However, there is currently insufficient information regarding the prognostic impact of high admission glucose levels of non-diabetic septic patients admitted to the ICU (10).
Outcomes:
Main outcome: To study the correlation between high blood glucose levels (above 180 mg / dL) upon ICU admission of non-diabetic patients with sepsis, and 28-day mortality, compared to ICU admitted septic patients with normal blood glucose levels upon admission (less than 180 mg / dL and above 70 mg / dL).
Secondary outcomes: To study the correlation between high blood glucose levels (above 180 mg / dL) upon ICU admission of non-diabetic patients with sepsis, and morbidity parameters, such as ventilation days, vasopressor and inotropic support, need for dialysis, need for tracheostomy, APACHE-2 score and admission lactate level compared to ICU admitted septic patients with normal blood glucose levels upon admission (less than 180 mg / dL and above 70 mg / dL).
Materials and methods:
Study design: Cohort retrospective study. Study population: Non-diabetic patients aged 18-99 who were admitted to the ICU between 1.1.2014 and 30.1.2020 due to sepsis or septic shock.
Study groups: Group A - Patients with admission blood glucose level lower than 180 mg / dL (but higher than 70 mg / dL).
Group B- Patients with admission blood glucose level higher than 180 mg / dL. Inclusion criteria: 1. Patients admitted to the ICU between 1.1.2014-30.1.2020. 2. Diagnosis of sepsis or septic shock upon admission. 3. Age over 18 years. 4. No previous diagnosis of diabetes mellitus. Exclusion criteria: 1. Patients with prior diagnosis of diabetes mellitus. 2. Admission hypoglycemia (blood glucose levels below 70 mg / dL). 3. Patients who were given insulin or intravenous glucose before the first ICU blood glucose measured level.
Data collection: Observational data collection format from hospital files and computerized systems (Chameleon system and iMDsoft software).
Data to be collected: age, gender, ICU and hospital admission times, source of infection, ventilation days, pressor or inotropic support, 28-day mortality, past medical history including regular medications, APACHE-2 score, admission lactate level, need for dialysis and need for tracheostomy.
Study group size: 1000 patients. Statistical analysis: All the parameters will be statistically examined by a qualified statistician depending on the type of data. We will use the Chi square test to analyze the individual data and the Mann-Whitney test to analyze the continuous data.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group A- Normal ICU admission blood glucose level | – | Other: No intervention- observational studyPatients with admission blood glucose level lower than 180 mg / dL (but higher than 70 mg / dL). |
| Group B- High ICU admission blood glucose level | – | Other: No intervention- observational studyPatients with admission blood glucose level higher than 180 mg / dL. |
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Non-diabetic patients aged 18-99 who were admitted to the ICU between 1.1.2014 and 30.1.2020 due to sepsis or septic shock.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No intervention- observational studyNo intervention- observational study | Other | Group A- Normal ICU admission blood glucose level, Group B- High ICU admission blood glucose level |
Primary outcome
28-day mortality
Time frame: 28-day from ICU admission
To study the correlation between high blood glucose levels (above 180 mg / dL) upon ICU admission of non-diabetic patients with sepsis, and 28-day mortality, compared to ICU admitted septic patients with normal blood glucose levels upon admission (less than 180 mg / dL and above 70 mg / dL).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Mar 2024.
Related trials for Sepsis
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
Active, not recruiting
CT for Personalized Mechanical Ventilation
Ventilator-Induced Lung Injury, Sepsis Syndrome
RecruitingPhase 4
A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients
Infection, Sepsis
Not yet recruiting
Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial)
Acute-on-Chronic Liver Failure (ACLF)
Active, not recruitingPhase 4
Thymosin Alpha 1 and IgM Levels in Sepsis
Sepsis, Septic Shock
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sepsis, run by Meir Medical Center at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
28-day mortality (time frame: 28-day from ICU admission). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Mar 2024.